Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients

Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients

In head and neck squamous cell carcinoma (HNSCC), anti-PD-1 inhibitors are approved for recurrent/metastatic (R/M) disease and anticipated to expand to other indications. The impact of p16 status and anatomical site on overall survival (OS) in immunotherapy-treated HNSCC patients remains unresolved....

Full description

Bibliographic Details
Main Authors: Kate Clancy, Chelsea S. Hamill, W. Quinn O’Neill, Brandon Vu, Jason Thuener, Shanying Gui, Shawn Li, Nicole Fowler, Rod Rezaee, Pierre Lavertu, Jay Wasman, Monaliben Patel, Hira Shaikh, Eric Vick, Anant Madabhushi, Trisha M. Wise-Draper, Kyunghee Burkitt, Theodoros N. Teknos, Quintin Pan
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
anti-PD-1 therapy
checkpoint inhibition
head and neck squamous cell carcinoma
immunotherapy
and p16
Online Access:https://www.mdpi.com/2072-6694/13/19/4861

Internet

https://www.mdpi.com/2072-6694/13/19/4861

Similar Items